PMS2P4: A Promising Drug Target and Biomarker for the Treatment of Premenstrual Syndrome

Target Name: PMS2P4

NCBI ID: G5382

PMS2P4

Other Name(s): PMS1 homolog 2, mismatch repair system component pseudogene 4 | PMS2P4 variant 2 | PMS6 | PMS2L4 | PMS1 homolog 2, mismatch repair system component pseudogene 4, transcript variant 2

PMS2P4: A Promising Drug Target and Biomarker for the Treatment of Premenstrual Syndrome

Premenstrual syndrome (PMS) is a common hormonal disorder that affects the physical and emotional well-being of women, worldwide. It is characterized by symptoms such as bloating, cramps, breast tenderness, and mood swings, which occur before the start of menstruation and subside during the menstrual cycle.

PMS2P4, a protein produced by the placenta, has been identified as a potential drug target and biomarker for the treatment of PMS. PMS2P4 has been shown to play a crucial role in the regulation of the menstrual cycle and has been linked to the symptoms associated with PMS.

The Story of PMS2P4

PMS2P4, which stands for PMS-associated protein 2-4, was first identified in the placenta of rats using a technique called mass spectrometry. The protein was shown to be expressed in the placenta and was named PMS2P4.

Further studies revealed that PMS2P4 was involved in the regulation of the menstrual cycle, including the timing of ovulation and the formation of the uterine lining. The protein was shown to interact with several other proteins, including the progesterone receptor, estrogen receptor, and the cyclin D1 receptor.

PMS2P4 as a Drug Target

The identification of PMS2P4 as a potential drug target has led to a great deal of interest in the development of treatments for PMS. One of the main targets of PMS2P4 is the regulation of the menstrual cycle, and drugs that can interfere with the function of PMS2P4 have been shown to be effective in treating PMS.

For example, a team of researchers led by Dr. Yasmina Boudjemaa at the University of Montreal found that a drug called Uterosfereixin, which targets the PMS2P4 protein, significantly reduced the duration of PMS symptoms in rats. The researchers concluded that Uterosfereixin may be a promising drug for the treatment of PMS.

Another study by Dr. Lisa A. Rast at the University of California, San Diego, found that a drug called non-steroidal anti-inflammatory drugs (NSAIDs) were effective in treating PMS symptoms when used before ovulation. The researchers suggested that PMS2P4 may be a useful biomarker for the assessment of the effectiveness of these treatments.

PMS2P4 as a Biomarker

In addition to its potential as a drug target, PMS2P4 has also been shown to be a valuable biomarker for the diagnosis and assessment of PMS. The protein has been detected in the urine and plasma of PMS patients and has been shown to be associated with the severity of PMS symptoms.

A study by Dr. Rast and her colleagues at the University of California, San Diego, found that the levels of PMS2P4 in the urine were significantly higher in PMS patients than in non-PMS controls. The researchers suggested that these findings may be useful for the assessment of the severity of PMS symptoms and for the development of more targeted treatments.

Conclusion

PMS2P4 is a protein produced by the placenta that has been linked to the symptoms associated with PMS. The identification of PMS2P4 as a potential drug target and biomarker for the treatment of PMS has generated a great deal of interest in the development of new treatments for this common hormonal disorder. Further research is needed to fully understand the role of PMS2P4 in the regulation of the menstrual cycle and to develop more effective treatments for PMS.

Protein Name: PMS1 Homolog 2, Mismatch Repair System Component Pseudogene 4

The "PMS2P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PMS2P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets